NCT04173429View on ClinicalTrials.gov

Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Liver CirrhosisPortal Vein Thrombosis
Interventions
DRUG

Nadroparin calcium, warfarin

Nadroparin calcium subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.

Trial Locations (1)

250012

Department of Gastroenterology,Qilu Hospital,Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER

NCT04173429 - Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis | Biotech Hunter | Biotech Hunter